Cargando…

Biomarkers for Allogeneic HCT Outcomes

Allogeneic hematopoietic cell transplantation (HCT) remains the only curative therapy for many hematological malignant and non-malignant disorders. However, key obstacles to the success of HCT include graft-versus-host disease (GVHD) and disease relapse due to absence of graft-versus-tumor (GVT) eff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adom, Djamilatou, Rowan, Courtney, Adeniyan, Titilayo, Yang, Jinfeng, Paczesny, Sophie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186420/ https://www.ncbi.nlm.nih.gov/pubmed/32373125 http://dx.doi.org/10.3389/fimmu.2020.00673

Ejemplares similares

Gamma delta T-cell reconstitution after allogeneic HCT: A platform for cell therapy
por: Gaballa, Ahmed, et al.
Publicado: (2022)

Specifically differentiated T cell subset promotes tumor immunity over fatal immunity
por: Ramadan, Abdulraouf, et al.
Publicado: (2017)

Validated graft-specific biomarkers identify patients at risk for chronic graft-versus-host disease and death
por: Logan, Brent R., et al.
Publicado: (2023)

Editorial: Novel Immunological Biomarkers for Allogeneic HSCT Outcome
por: Greco, Raffaella, et al.
Publicado: (2021)

Maintenance therapy for AML after allogeneic HCT
por: Nayak, Rahul K., et al.
Publicado: (2022)

Novel Biomarkers for Outcome After Allogeneic Hematopoietic Stem Cell Transplantation
por: Chen, Sophia, et al.
Publicado: (2020)

The contribution of the intestinal microbiome to immune recovery after HCT
por: Wolfe, Alex E., et al.
Publicado: (2022)

Various Forms of Tissue Damage and Danger Signals Following Hematopoietic Stem-Cell Transplantation
por: Ramadan, Abdulraouf, et al.
Publicado: (2015)

The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases
por: Griesenauer, Brad, et al.
Publicado: (2017)

The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies
por: Passweg, Jakob R., et al.
Publicado: (2019)

Editorial: Danger Signals Triggering Immune Response and Inflammation
por: Ramadan, Abdulraouf, et al.
Publicado: (2017)

Early Respiratory Viral Acquisition after Allogeneic Hematopoietic Cell Transplant (HCT)
por: Boonyaratanakornkit, Jim, et al.
Publicado: (2019)

Assessment of Serology after Sars-Cov-2 Vaccine in Allogeneic HCT Recipients
por: Baker, Melissa, et al.
Publicado: (2021)

T Cell Subsets in Graft Versus Host Disease and Graft Versus Tumor
por: Jiang, Hua, et al.
Publicado: (2021)

Predicting the Clinical Outcome of Allogeneic Hematopoietic Stem Cell Transplantation: The Long and Winding Road toward Validated Immune Biomarkers
por: Forcina, A., et al.
Publicado: (2013)

Time series clustering of T cell subsets dissects heterogeneity in immune reconstitution and clinical outcomes among MUD-HCT patients receiving ATG or PTCy
por: Leserer, Saskia, et al.
Publicado: (2023)

Granzyme A–producing T helper cells are critical for acute graft-versus-host disease
por: Park, Sungtae, et al.
Publicado: (2020)

281. Detecting bacterial sepsis among allogeneic HCT recipients with population-specific bedside tools
por: Lind, Margaret, et al.
Publicado: (2020)

1548. Risk of Severe Herpes Zoster (HZ) in Allogeneic Hematopoietic-Cell Transplantation (HCT) Recipients
por: Baumrin, Emily, et al.
Publicado: (2018)

1001. Feasibility and Outcomes of a Pre-Transplant Antibiotic Allergy Evaluation Program for Allogeneic Hematopoietic Cell Transplant (HCT) Candidates
por: Liu, Catherine, et al.
Publicado: (2019)

Interleukin-6 as Biomarker for Acute GvHD and Survival After Allogeneic Transplant With Post-transplant Cyclophosphamide
por: Greco, Raffaella, et al.
Publicado: (2019)

1753. Adherence and Immunogenicity of Early Vaccination in Pediatric Allogeneic Hematopoietic Cell Transplantation (allo-HCT) Recipients
por: Danino, Dana, et al.
Publicado: (2019)

Anti-thymocyte globulin with CsA and MMF as GVHD prophylaxis in nonmyeloablative HLA-mismatched allogeneic HCT
por: van der Velden, Walter J. F. M., et al.
Publicado: (2021)

CMV reactivation after allogeneic HCT is associated with a reduced risk of relapse in acute lymphoblastic leukemia
por: Akahoshi, Yu, et al.
Publicado: (2023)

Torque Teno Virus as a Potential Biomarker for Complications and Survival After Allogeneic Hematopoietic Stem Cell Transplantation
por: Pradier, Amandine, et al.
Publicado: (2020)

Donor-Specific Anti-HLA Antibodies in Allogeneic Hematopoietic Stem Cell Transplantation
por: Morin-Zorman, Sarah, et al.
Publicado: (2016)

A Systematic Review of the Literature and Perspectives on the Role of Biomarkers in the Management of Malnutrition After Allogeneic Hematopoietic Stem Cell Transplantation
por: Morello, Enrico, et al.
Publicado: (2021)

Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry
por: Busca, Alessandro, et al.
Publicado: (2023)

Review of Genetic Variation as a Predictive Biomarker for Chronic Graft-Versus-Host-Disease After Allogeneic Stem Cell Transplantation
por: Partanen, Jukka, et al.
Publicado: (2020)

Cytotoxic Pathways in Allogeneic Hematopoietic Cell Transplantation
por: Du, Wei, et al.
Publicado: (2018)

Biomarkers for Early Complications of Endothelial Origin After Allogeneic Hematopoietic Stem Cell Transplantation: Do They Have a Potential Clinical Role?
por: Lia, Giuseppe, et al.
Publicado: (2021)

Graft Immune Cell Composition Associates with Clinical Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with AML
por: Impola, Ulla, et al.
Publicado: (2016)

LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors
por: Cruz, David, et al.
Publicado: (2023)

How to improve the outcomes of elderly acute myeloid leukemia patients through allogeneic hematopoietic stem cell transplantation
por: Jiang, Shan, et al.
Publicado: (2023)

1077. Infectious complications after second allogeneic hematopoietic cell transplant (allo-HCT) in adult patients with hematological malignancies
por: Maurer, Stephen, et al.
Publicado: (2020)

A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCT
por: Schäfer, Henning, et al.
Publicado: (2021)

CNS Involvement at Initial Diagnosis and Risk of Relapse After Allogeneic HCT for Acute Lymphoblastic Leukemia in First Complete Remission
por: Kharfan-Dabaja, Mohamed A., et al.
Publicado: (2022)

Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting
por: Pfeiffer, Thomas, et al.
Publicado: (2023)

Monitoring of strength, inflammation and muscle function in allogenic stem-cell transplantation patients – a pilot study for novel biomarker and risk stratification determination
por: Schulz, Sebastian Viktor Waldemar, et al.
Publicado: (2023)

Autoimmunity Following Allogeneic Hematopoietic Stem Cell Transplantation
por: Buxbaum, Nataliya Prokopenko, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hjr52nhtmnba2kpdj91eta99o1